Integral Health Asset Management LLC Buys New Stake in Dianthus Therapeutics, Inc. $DNTH

Key Points

• Integral Health Asset Management LLC bought a new position of 150,000 shares of Dianthus Therapeutics (~$5.9M), representing about 0.47% ownership.
• Dianthus announced an early Phase‑3 "go" decision and closed an upsized underwritten offering that raised roughly $719 million, sparking a strong rally and multiple analyst upgrades.
• Despite the financing, the company remains a pre‑profit, high‑burn biotech after an EPS miss and extremely negative margins, and insiders have sold about 200,430 shares (~$16.3M) in the past three months.

Integral Health Asset Management LLC purchased a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 150,000 shares of the company's stock, valued at approximately $5,902,000. Integral Health Asset Management LLC owned 0.47% of Dianthus Therapeutics as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust lifted its position in shares of Dianthus Therapeutics by 131.7% during the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company's stock worth $37,000 after purchasing an additional 540 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Dianthus Therapeutics during the 2nd quarter valued at approximately $27,000. Russell Investments Group Ltd. bought a new position in Dianthus Therapeutics during the 3rd quarter worth $64,000. Tower Research Capital LLC TRC increased its position in Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company's stock worth $80,000 after buying an additional 3,317 shares during the period. Finally, Glenmede Investment Management LP acquired a new stake in Dianthus Therapeutics in the third quarter worth $213,000. Institutional investors and hedge funds own 47.53% of the company's stock.

Key Headlines Impacting Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Company news: management announced an early Phase‑3 "go" decision and an upsized capital raise that sparked the recent rally; market reaction was enthusiastic because the program advancement de‑risked the story while the raise funds development and operations. Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision
• Positive Sentiment: Financing closed: Dianthus completed an upsized underwritten offering that generated roughly $719M of gross proceeds (including full exercise of the underwriters' option), strengthening the company's cash runway for clinical work. This is a clear near‑term liquidity positive for investors. Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering...
• Positive Sentiment: Analyst upgrades: multiple firms (Raymond James, Wedbush, Robert W. Baird) issued bullish notes or raised their stance, which helped lift sentiment and trading activity. Upgrades add distribution and can attract momentum buyers. Dianthus Therapeutics NASDAQ: DNTH Raised to "Strong-Buy" at Raymond James Financial
• Positive Sentiment: Trading flow: the stock saw a large volume increase after analyst coverage/bullish headlines, indicating active repositioning by investors around the financing and clinical update. Higher volume can amplify price moves in either direction. Dianthus Therapeutics NASDAQ: DNTH Sees Large Volume Increase Following Analyst Upgrade
• Neutral Sentiment: Short-interest note: the most recent short‑interest data reported an anomalous zero‑share figure and essentially a 0.0 days‑to‑cover metric — likely a reporting quirk rather than a meaningful signal; treat with caution.
• Negative Sentiment: Analyst/model risk: HC Wainwright lowered near‑term and FY2026–FY2028 EPS forecasts substantially even while keeping a Buy rating and a high target; the cuts highlight expected cash burn and timing risk, which can pressure near‑term sentiment and invite profit‑taking.
• Negative Sentiment: Operational/financial backdrop: recent quarterly results included an EPS miss and very negative margins/returns, reminding investors that Dianthus remains a pre‑profit, high‑burn biotech—so upside is dependent on clinical progress and successful use of the new capital.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH opened at $77.86 on Friday. The firm has a market cap of $3.46 billion, a P/E ratio of -18.99 and a beta of 1.56. The stock has a fifty day moving average price of $52.53 and a two-hundred day moving average price of $42.56. Dianthus Therapeutics, Inc. has a 1 year low of $13.36 and a 1 year high of $88.02.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its earnings results on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. The firm had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.40 million. On average, research analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on DNTH shares. Jefferies Financial Group set a $98.00 price target on shares of Dianthus Therapeutics and gave the company a "buy" rating in a report on Monday. Truist Financial increased their price objective on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a "buy" rating in a report on Monday, March 9th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Dianthus Therapeutics in a research report on Wednesday, January 21st. Robert W. Baird boosted their target price on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the company an "outperform" rating in a research note on Tuesday. Finally, Oppenheimer upped their target price on shares of Dianthus Therapeutics to $145.00 and gave the stock an "outperform" rating in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $115.33.

Insider Transactions at Dianthus Therapeutics

In other news, CEO Marino Garcia sold 122,918 shares of the company's stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $81.49, for a total transaction of $10,016,587.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CAO Edward Carr sold 43,682 shares of the business's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $81.49, for a total value of $3,559,646.18. The SEC filing for this sale provides additional information. Insiders have sold 200,430 shares of company stock valued at $16,332,702 over the last three months. Company insiders own 8.15% of the company's stock.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

Want to see what other hedge funds are holding DNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.